Wegovy tablets in the UK: what the MHRA approved and how they work

Medically reviewed by: Dr Abdullah and the Rightangled clinical team - GPhC-registered independent prescribers

Reading time: 8 minutes · Guidance verified: August 2026

The Wegovy tablets UK approval came on 11 June 2026, when the MHRA authorised the first GLP-1 receptor agonist tablet for weight loss and weight management in this country. Until that point, every GLP-1 weight management medicine licensed in Britain was an injection.

A tablet sounds like the simpler option, and for many people it is. But oral semaglutide comes with administration rules that are stricter than most patients expect, and getting them wrong measurably reduces how much of the medicine reaches your bloodstream. This guide covers what was actually authorised, how the tablets must be taken, what the trial evidence shows, and who they are and are not suitable for.

What are Wegovy tablets?

Wegovy tablets contain semaglutide, a GLP-1 receptor agonist. GLP-1 is a hormone the body releases from the gut after eating. Semaglutide mimics it, acting on the appetite-regulating regions of the brain to reduce hunger and food cravings, slowing the rate at which food leaves the stomach so fullness lasts longer, and supporting blood glucose regulation by increasing insulin release when glucose is high.

The active ingredient is the same one used in the Wegovy injection. The formulations are not interchangeable. Semaglutide is a peptide, a relatively large molecule that digestive enzymes readily break down, so the oral version is paired with an absorption enhancer and uses a completely different dose range. A daily 25 mg tablet is not equivalent to a 25 mg injection, and doses cannot be converted informally between the two.

Wegovy tablets UK approval: what the MHRA authorised

The authorisation was granted to Novo Nordisk on 11 June 2026. Alongside a reduced-calorie diet and increased physical activity, the tablet may be prescribed to adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related comorbidity. That is the core of the licence.

Julian Beach, Executive Director of Healthcare Quality and Access at the MHRA, confirmed the tablet had met the agency's standards of safety, quality and effectiveness, and restated that, as with all GLP-1 receptor agonists, it remains a prescription-only medicine.

One detail from the authorisation is often missed: patients already being treated privately with a 2.4 mg semaglutide injection once weekly can be transitioned directly to 25 mg tablets once daily, without stepping back through the lower doses. If you are on a different injection dose, your prescriber will advise the appropriate starting point rather than applying that conversion.

How to take Wegovy tablets correctly

This is the part that most affects whether the medicine works, and it is stricter than a typical tablet regimen.

• Take one tablet once daily, first thing in the morning.

• The stomach must be empty, after fasting for at least 8 hours. That fast includes water.

• Swallow the tablet whole with a sip of plain water, no more than roughly 120 ml. More water than that reduces absorption.

• Do not split, crush or chew it.

• Wait at least 30 minutes before any food, any other drink, or any other oral medicine.

The reason is mechanical rather than arbitrary. The absorption enhancer works in a small area of the stomach lining, and only for a short window. Food, other liquids and competing medicines all interfere with that window. Eating or drinking sooner than 30 minutes lowers how much semaglutide is absorbed, which is why the instruction appears in the Patient Information Leaflet rather than as general advice.

If you miss a dose, skip it and take the next scheduled dose the following morning. Never double up to compensate.

Wegovy tablets UK dosing schedule

Treatment starts low and increases gradually, a process called dose titration, which gives the body time to adapt and reduces the likelihood of side effects.

If side effects are difficult at any step, a prescriber may hold you at that dose for longer rather than escalating on schedule.

How effective are Wegovy tablets?

The evidence behind the Wegovy tablets UK licence comes from the Phase 3 OASIS 4 trial, which followed 307 adults with obesity, or overweight with at least one weight-related condition, for 64 weeks on 25 mg once daily.

Two figures are reported, and the difference between them matters. Among participants who adhered fully to treatment, mean body weight reduction was 16.6% against 2.7% on placebo. Under the broader treatment-policy analysis, which also counts participants who stopped treatment or added other interventions, the average was 13.6% against 2.2%. Around 30% of those on oral semaglutide lost 20% or more of their body weight, compared with roughly 3% on placebo.

The 16.6% figure is the one most often quoted. The 13.6% figure is the more realistic expectation for a general population, because in practice not everyone completes a full course. Trial findings also suggested improvements in some cardiometabolic markers, though these should not be read as proven cardiovascular outcome benefits without dedicated outcome data.

Results vary considerably between individuals, influenced by starting weight, how consistently the daily dosing rules are followed, tolerability, and the diet and activity changes made alongside treatment.

Side effects

The most common side effects are gastrointestinal: nausea, diarrhoea, constipation and vomiting, along with headache, indigestion, abdominal pain and fatigue. These are typically most noticeable when starting treatment and after each dose increase, and often settle as the body adapts.

Less common effects include dizziness, bloating, reflux, taste changes, gallstones and hair loss. Seek urgent medical advice for signs of an allergic reaction, severe and persistent stomach or back pain, or sudden changes to your eyesight.

Anyone who suspects a side effect should speak to a doctor, pharmacist or nurse, and report it through the MHRA Yellow Card scheme. We cover the wider safety profile of this active ingredient in our guide to Wegovy safety.

Interactions and who should not take them

Because absorption depends on that 30 minute window, other oral medicines are affected more than with most treatments. Tell your prescriber if you take levothyroxine for thyroid conditions or oral anticoagulants such as warfarin, both of which need careful timing around the dose.

The tablets are not suitable during pregnancy or breastfeeding, and treatment should stop two months before trying to conceive. Tell your prescriber if you have a history of pancreatitis, severe heart failure, gastroparesis, diabetic eye disease, severe kidney or liver problems, or if you have surgery planned under general anaesthetic.

Wegovy tablets UK availability and NHS access

The tablets are licensed in the UK but are not currently available on the NHS. Decisions on NHS use follow established processes, including evaluation by the National Institute for Health and Care Excellence. Until that concludes, access is through private prescription only, following a clinical assessment. You can review Wegovy tablets and available doses on our treatment page.

They are also prescription-only, so they cannot be bought over the counter, and medicines sourced from unregulated sellers carry real risk. Supply should always come from a registered pharmacy against a valid prescription. Wegovy tablets UK pricing is set privately rather than centrally, and varies by dose, because each step of the titration uses a different tablet strength. Patients based elsewhere in Europe can explore weight management options through Medetone, our pan-European service.

Frequently asked questions

Are Wegovy tablets UK approved?

Yes. The MHRA authorised them on 11 June 2026 for weight loss and weight management in adults meeting the BMI criteria.

How long do I need to take them?

Because the maintenance dose is only reached at around month four, meaningful results take several months. Progress is typically reviewed at six months against a 5% body weight reduction benchmark.

What happens if I stop?

There are no withdrawal effects, but appetite gradually returns to its previous level, and some or all of the weight lost may return without sustained lifestyle changes.

Is there an alternative oral GLP-1?

Yes. Foundayo (orforglipron) was authorised in August 2026 and works on the same pathway, with no fasting or food restrictions. We have covered it in our guide to Foundayo.

"The daily routine is what determines the outcome here. An eight hour fast and a thirty minute wait sounds trivial until you have to do it every morning for a year. We would rather have that conversation before someone starts than three months in."

Dr Abdullah, Medical Lead at Rightangled

At Rightangled, every weight management consultation is reviewed by GPhC-registered independent prescribers as soon as the consultation is submitted. Treatment is supplied only where it is clinically appropriate.

Verify us before you trust us

• GPhC registered pharmacy, registration number 9011933

• LegitScript certified

• Verified patient reviews on Trustpilot

References

1. MHRA. First GLP-1 tablet for weight loss approved in the UK. GOV.UK, 11 June 2026. MHRA approval press release

2. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med, 2025. OASIS 4 trial abstract on PubMed

This article is for information only and is not a substitute for individual medical advice. Semaglutide tablets are a prescription-only medicine. Suitability, dosing and expected outcomes vary between individuals and must be assessed by a prescriber. Always read the Patient Information Leaflet. Last reviewed August 2026.